Comparison of Clinical Characterization and Therapeutic Strategies between Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
Open Access
- 1 July 2026
- journal article
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 33 (7) , 884-894
Abstract
Aims: Homozygous Familial hypercholesterolemia (HoFH) is a rare genetic disease characterized by very high levels of low-density lipoprotein cholesterol (LDL-C). Owing to LDL receptor activity being completely or nearly all lost in HoFH, LDL-C levels greatly exceed normal levels, and are even higher than in heterozygous (HeFH), which can cause fatal cardiovascular disease even in infancy. The current study updates differences in clinical characterization, therapeutic strategies and cardiovascular outcomes between HoFH and HeFH.Methods: A total of 157 patients who were genetically or clinically diagnosed with FH (HoFH: 15, HeFH: 142) were retrospectively analyzed. Clinical characteristics, lipid profiles and atherosclerotic prognosis were evaluated between HoFH and HeFH patients.Results: Age and sex were similar between the two groups. Untreated LDL-C in HoFH was about double that in HeFH (498.4±164.3 vs. 232.0±60.5 mg/dL, p<0.001), while on-treatment LDL-C with lipid lowering therapies did not differ significantly (83.8±59.1 vs. 127.1±59.6 mg/dL, p = 0.15). There was wide diversity in lipid lowering therapies between the two groups and a significantly higher prevalence of coronary artery and valvular disease in HoFH. Consequently, HoFH patients were more likely to receive percutaneous and surgical interventions at a younger age compared to HeFH patients.Conclusions: The findings of this observational study show the clinical relevance of FH. Although both HeFH and HoFH are inherited disorders of lipoprotein metabolism, HoFH should be treated with a different, stricter therapeutic strategy to prevent premature ASCVD.Keywords
This publication has 35 references indexed in Scilit:
- Early diagnosis and treatments in childhood are associated with better prognosis in patients with familial hypercholesterolemiaAmerican Journal of Preventive Cardiology, 2022
- Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event RiskJACC, 2020
- A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemiaJournal of Clinical Lipidology, 2020
- Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery diseaseJournal of Clinical Lipidology, 2018
- Impact of Lipids on Cardiovascular HealthJACC, 2018
- Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemiaJournal of Clinical Lipidology, 2016
- Fatal Myocardial Infarction at 4.5 Years in a Case of Homozygous Familial Hypercholesterolaemia2011
- Sudden Death in a 4-Year-Old Boy: A Near-Complete Occlusion of the Coronary Artery Caused by an Aggressive Low-Density Lipoprotein Receptor Mutation (W556R) in Homozygous Familial HypercholesterolemiaThe Journal of Pediatrics, 2011
- Standard method for ultrasound evaluation of carotid artery lesionsJournal of Medical Ultrasonics, 2009
- Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial HypercholesterolemiaThe American Journal of Cardiology, 2008